A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with Small Cell Lung Cancer (SCLC) (DeLLphi-309)

This study is being done to learn more about tarlatamab in people with Small Cell Lung Cancer (SCLC; a type of fast-growing cancer that forms in tissues of the lung and can spread to other parts of the body) that has progressed following platinum-based chemotherapy (a type of cancer treatment that involves drugs containing platinum ion compounds). This cancer type may have an excess amount of protein markers (e.g., delta-like ligand 3 [DLL3]; a protein possibly causing cells to grow more quickly and multiply abnormally).
This study is being done to see how well tarlatamab works and whether it causes any side effects. This study will also look at what doses of tarlatamab are safe for people to take. The drug (tarlatamab) you will get as part of this study will be called a study drug.